NEW YORK – Thermo Fisher Scientific said on Monday that it has received CE-marking for its TaqPath COVID-19, Flu A/B, RSV Combo Kit for the diagnosis of SARS-CoV-2, influenza A/B, and respiratory syncytial virus A/B infections.
The PCR-based kit allows laboratories to test for the diseases, which share clinical symptoms, in approximately three hours. Test results are analyzed using the Applied Biosystems Pathogens Interpretive Software, which automatically converts genetic analysis data into a report, reducing the risk of user interpretation error.
The new kit complements Thermo Fisher's previously launched TaqPath COVID-19 Combo Kit and RT-PCR CE-IVD.